ClinicalTrials.gg

Program

ARGX-124

A development code.

Its studies are led by argenx.

Furthest: phase 1, since Jan 22, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenx11 open or runningphase 1since Jan 22, 2026Jan 22, 2026Dec 31, 2026phase 1 · NCT07377396

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 22, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07377396 · 104 planned · Canada

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Healthy VolunteersNCT07377396

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07377396Healthy Volunteers · Canada1RecruitingDec 31, 2026104

How it is read

Names in the registry

  • “ARGX-124”, 1 entry

Codes read as this program: ARGX124.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.